H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Verve Therapeutics with a Buy rating and $15 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics price target lowered to $40 from $56 at Stifel
- Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
- RBC remains buyer of Verve Therapeutics after enrollment pause
- Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt
- Verve Therapeutics down 33% at $8.50 after pausing Heart-1 trial of VERVE-101